Circulating melanoma cells relative to disease stage

Document Type



Edith Cowan University Research Online


Faculty of Computing Health and Science

School or Research Centre

School of Exercise, Biomedical and Health Sciences


National Health and Medical Research Council, Cancer Council of Western Australia, Cancer and Palliative Care Research and Evaluation Unit


This collection comprises clinical data with four-five melanoma markers per patient. collected over three years of data comprising genetic tests, clinical data and clinical evaluations. The dataset includes names of genes being investigated: by clinical stage of metastasis, and by drug treatments and is stored in Excel file format. The dataset supports research on the PAX3 gene and its role as a key regulator of the myriad steps in melanocytic cell determination. The purpose of the research is (1) to identify the transcriptional profile of circulating melanoma cells relative to disease stage and (2) to test the efficacy of using circulating cells as a prognostic marker. The data has the potential to be used by others to correlate new research data using different methodologies.

Research Activity Title

Characterisation of circulating melanoma cells in patient blood

Research Activity Description

Melanoma is a highly aggressive form of skin cancer that has a tendency to metastasise. It accounts for around 80% of skin cancer related deaths. In its early stages, the 5 year survival rate of patients is greater than 90% following surgical excision of an in situ tumour. However, following metastasis of the tumour, the 5 year survival rate declines to 5-35%. Due to the correlation between metastasis and declining survival, research studies have attempted to identify potential metastasis as early as possible. The Melanoma Research Group at Edith Cowan University (ECU) is developing a blood test for diagnosis and prognosis of melanoma. Thus far the ECU researchers have developed a test that can detect circulating melanoma cells in peripheral blood of patients. The test can be used for diagnostic purposes and has been tested in over 250 patients with a 79% detection rate. Development of a prognostic blood test that can detect melanoma cells at early stages of the disease has the potential to benefit all melanoma sufferers and potential melanoma sufferers.

Start of data collection time period


End of data collection time period




Access Rights

metadata only record


Edith Cowan University owns the rights to this collection.

Contact Dr Mel Ziman to determine access conditions.

Melanie Ziman:

This item is not available for download.


Article Location